Ovidiu Bălăcescu

ORCID: 0000-0003-0253-7103
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • MicroRNA in disease regulation
  • Circular RNAs in diseases
  • Cancer-related molecular mechanisms research
  • Cancer Cells and Metastasis
  • Colorectal Cancer Treatments and Studies
  • Extracellular vesicles in disease
  • Cancer Treatment and Pharmacology
  • Molecular Biology Techniques and Applications
  • Cancer-related Molecular Pathways
  • Angiogenesis and VEGF in Cancer
  • Gene expression and cancer classification
  • Plant Genetic and Mutation Studies
  • RNA Interference and Gene Delivery
  • Cancer, Lipids, and Metabolism
  • Pancreatic and Hepatic Oncology Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer Diagnosis and Treatment
  • Gastric Cancer Management and Outcomes
  • Cancer Immunotherapy and Biomarkers
  • Ovarian cancer diagnosis and treatment
  • Cell Image Analysis Techniques
  • Genetic factors in colorectal cancer
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Glutathione Transferases and Polymorphisms
  • Prostate Cancer Treatment and Research

Institute of Oncology Prof. Dr. Ion Chiricuta
2015-2024

Iuliu Hațieganu University of Medicine and Pharmacy
2014-2023

Victor Babeș University of Medicine and Pharmacy Timișoara
2022

Instituto de Salud Carlos III
2012

Cancer Institute (WIA)
2009-2010

KU Leuven
2006

Morpho (United States)
2006

Erasmus MC
2006

Gene expression profiling data for human primary cutaneous melanomas are scarce because of the lack retrospective collections frozen tumors. To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated relationship between gene profiles clinical outcome a cohort patients with melanoma.Labeled complementary RNA (cRNA) from each tissue sample was hybridized to pangenomic 44K 60-mer oligonucleotide microarray. Class comparison class...

10.1093/jnci/djj103 article EN JNCI Journal of the National Cancer Institute 2006-04-04

Flavan-3-ols are involved in multiple metabolic pathways that induce inhibition of cell proliferation. We studied the structure-activity relationship gallic acid (GA) and four flavan-3-ols: epigallocatechin gallate (EGCG), (EGC), catechin (C), epicatechin (EC). measured viability by MTT assay we determined concentration testing compound required to reduce 50% (IC50). All tested compounds showed a dose-dependent time-dependent inhibitory antiproliferative effect on Hs578T cells; IC50 values...

10.3390/ijms12129342 article EN International Journal of Molecular Sciences 2011-12-13

Sixteen hydrazinyl-thiazolo arene ruthenium complexes of the general formula [(η(6)-p-cymene)Ru(N,N'-hydrazinyl-thiazolo)Cl]Cl were synthesized. All tested in vitro for their antiproliferative activity on three tumor cell lines (HeLa, A2780, and A2780cisR) a noncancerous line (HFL-1). A superior cytotoxic as compared to cisplatin oxaliplatin, both cisplatin-sensitive resistant ovarian cancer cells, was observed. In addition, biological two selected derivatives evaluated using microarray gene...

10.1021/acs.jmedchem.5b00855 article EN publisher-specific-oa Journal of Medicinal Chemistry 2015-10-21

Colorectal cancer (CRC) represents the third most diagnosed type of worldwide with high mortality and an increased incidence rate.

10.1039/c9fo01014a article EN Food & Function 2019-01-01

Advanced squamous cervical cancer, one of the most commonly diagnosed cancers in women, still remains a major problem oncology due to treatment failure and distant metastasis. Antitumor therapy is both intrinsic acquired resistance; resistance often decisive for response. In this study, we investigated specific pathways molecules responsible baseline locally advanced cancer. Twenty-one patients with cell carcinoma were enrolled study. Primary biopsies harvested prior analyzed whole human...

10.1186/1471-2407-14-246 article EN cc-by BMC Cancer 2014-04-08

Neo-adjuvant therapy (NAT) is increasingly used in the clinic for treatment of breast cancer (BC). Pathological response to NAT has been associated with improved patients’ survival; however, current techniques employed assessing tumor have significant limitations. Small EVs (sEVs)-encapsulated miRNAs emerged as promising new biomarkers diagnosis and prediction. Therefore, our study aims explore predictive value these pathological BC. By employing bioinformatic tools, we selected a set...

10.3390/ijms232012625 article EN International Journal of Molecular Sciences 2022-10-20

In women, breast cancer is the most commonly diagnosed (11.7% of total cases) and leading cause death (6.9%) worldwide. Bioactive dietary components such as Sea buckthorn berries are known for their high carotenoid content, which has been shown to possess anti-cancer properties. Considering limited number studies investigating bioactive properties carotenoids in cancer, aim this study was investigate antiproliferative, antioxidant, proapoptotic saponified lipophilic extract (LSBE) two cell...

10.3390/molecules28114486 article EN cc-by Molecules 2023-06-01

The major green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) has been shown to exhibit antitumour activities in several tumour models. One of the possible mechanisms by which EGCG can inhibit cancer progression is through modulation angiogenesis signalling cascade. cells' ability tightly adhere endothelium a very important process metastatic process, because once disseminated into bloodstream cells must re-establish adhesive connections order extravasate target tissues. In this...

10.1111/j.1582-4934.2011.01346.x article EN cc-by Journal of Cellular and Molecular Medicine 2011-05-24

Background and Objectives: Over decades, prostate cancer (PCa) has become one of the leading causes mortality in men. Extensive evidence exists that microRNAs (miRNAs or miRs) are key players PCa a new class non-invasive biomarkers. Materials Methods: We performed miRNA profiling plasma tissues patients attempted validation candidate individual miRs as Results: The comparison tissue results revealed five commonly dysregulated miRs, namely, miR-130a-3p, miR-145-5p, miR-148a-3p, miR-150-5p,...

10.3390/medicina55090564 article EN cc-by Medicina 2019-09-03

The status of predictive biomarkers in metastatic colorectal cancer is currently underdeveloped. Our study aimed to investigate the value six circulating exosomal miRNAs derived from plasma (miR-92a-3p, miR-143-3p, miR-146a-5p, miR-221-3p, miR-484, and miR-486-5p) for chemosensitivity, resistance patterns, survival. Thirty-one patients were selected before receiving first-line irinotecan- or oxaliplatin-based chemotherapy. Blood samples harvested at baseline 4-6 months after initiation...

10.3390/ijms241310622 article EN International Journal of Molecular Sciences 2023-06-25

Cancer cells frequently adopt cellular and molecular alterations acquire resistance to cytostatic drugs. Chemotherapy with oxaliplatin is among the leading treatments for colorectal cancer a response rate of 50%, inducing intrastrand cross-links on DNA. Despite this drug's efficiency, develops in nearly all metastatic patients. Chemoresistance being crucial importance clinical efficiency study aimed contribute identification description some induced by prolonged therapy. Resistance was...

10.1186/1471-2164-14-480 article EN cc-by BMC Genomics 2013-01-01

MicroRNAs (miRNAs), a class of small non-coding RNAs represent potential biomarkers for colorectal cancer (CRC). The study hypothesized that miRNAs associated with liver metastases may also contribute to assessing treatment response when plasma exosomes. In this study, we used two sets biological samples, collection tumor tissues harvested from patients CRC and without metastases, FOLFOX4/FOLFIRI regimens. We investigated 10 target in the tissue 28 identified miR-125b-5p, miR-17-5p,...

10.3389/fonc.2021.651380 article EN cc-by Frontiers in Oncology 2021-05-18
Coming Soon ...